BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

Multiple developers of connected diabetes hardware have announced plans this week to link their insulin pumps with continuous ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile ...

The miniaturized surgical robot maker Virtual Incision has pinched a new CEO, as it aims to expand its commercial reach ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...